Search Results - "VINIOU, Nora"

Progressive multifocal leukoencephalopathy in the context of newer therapies in hematology and review of new treatment strategies by Diamantopoulos, Panagiotis T., Kalopisis, Konstantinos, Tsatsou, Aikaterini, Efthymiou, Athina, Giannakopoulou, Nefeli, Hatzidavid, Sevastianos, Viniou, Nora‐Athina

“…Progressive multifocal leukoencephalopathy (PML) is a rare, often fatal demyelinating disease of the central nervous system (CNS) caused by the reactivation of…”
Get full text

The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms by Diamantopoulos, Panagiotis T., Solomou, Elena, Symeonidis, Argiris, Pappa, Vasiliki, Kotsianidis, Ioannis, Galanopoulos, Athanasios, Pontikoglou, Charalampos, Anagnostopoulos, Achilles, Vassilopoulos, George, Zikos, Panagiotis, Hatzimichael, Eleftheria, Papaioannou, Maria, Megalakaki, Aekaterini, Vassilakopoulos, Theodoros, Dimou, Maria, Tsokanas, Dimitrios, Papoutselis, Menelaos‐Konstantinos, Papageorgiou, Sotirios, Kourakli, Alexandra, Papadaki, Helen, Panayiotidis, Panayiotis, Viniou, Nora‐Athina

Get full text

The effect of 5‐azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes by Diamantopoulos, Panagiotis T., Symeonidis, Argiris, Pappa, Vasiliki, Kotsianidis, Ioannis, Galanopoulos, Athanasios, Pontikoglou, Charalampos, Anagnostopoulos, Achilles, Vassilopoulos, George, Zikos, Panagiotis, Hatzimichael, Eleftheria, Papaioannou, Maria, Megalakaki, Aekaterini, Repousis, Panagiotis, Kotsopoulou, Maria, Dimou, Maria, Solomou, Elena, Dryllis, Georgios, Tsokanas, Dimitrios, Papoutselis, Menelaos‐Konstantinos, Papageorgiou, Sotirios, Kyrtshonis, Marie‐Christine, Kourakli, Alexandra, Papadaki, Helen, Panayiotidis, Panayiotis, Viniou, Nora‐Athina

“…Summary The regimen of 5‐azacytidine for patients with myelodysplastic syndrome (MDS) has remained unchanged since its first approval. Although several…”
Get full text

A case report of a fulminant Aeromonas hydrophila soft tissue infection in a patient with acute lymphoblastic leukemia harboring a rare translocation by Charakopoulos, Emmanouil, Diamantopoulos, Panagiotis T, Zervakis, Konstantinos, Giannakopoulou, Nefeli, Psichogiou, Mina, Viniou, Nora-Athina

“…are gram-negative opportunistic bacteria, mainly found in aquatic environments. Hematologic patients are particularly at risk of soft tissue infections and…”
Get full text

The genetics of myelodysplastic syndromes and the opportunities for tailored treatments by Kontandreopoulou, Christina-Nefeli, Kalopisis, Konstantinos, Viniou, Nora-Athina, Diamantopoulos, Panagiotis

“…Genomic instability, microenvironmental aberrations, and somatic mutations contribute to the phenotype of myelodysplastic syndrome and the risk for…”
Get full text

Factors affecting response to 5-azacytidine and prognosis of myelodysplastic syndrome. Is long-term survival a realistic goal? by Diamantopoulos, Panagiotis T., Viniou, Nora-Athina

“…•Response to 5-azacytidine is a major determinant of prognosis of patients with myelodysplastic syndrome.•Factors affecting treatment response are essential…”
Get full text

Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches by Diamantopoulos, Panagiotis T, Viniou, Nora-Athina

“…Atypical chronic myelogenous leukemia (aCML), negative is a rare myelodysplastic/myeloproliferative neoplasm, usually manifested with hyperleukocytosis without…”
Get full text

Validation of the simplified International Prognostic Score3 in a Hellenic cohort of patients with advanced‐stage Hodgkin‐lymphoma by Asimakopoulos, John V., Angelopoulou, Maria K., Arapaki, Maria‐Panagiota, Kanellopoulos, Alexandros, Dimou, Maria, Giakoumis, Xanthoula, Konstantinou, Eliana, Belia, Marina, Chatzidimitriou, Chrysovalantou, Sachanas, Sotirios, Iliakis, Theodoros, Kyrtsonis, Marie‐Christine, Siakantaris, Marina P., Viniou, Nora‐Athina, Variamis, Eleni, Kontopidou, Flora N., Pangalis, Gerassimos A., Panayiotidis, Panayiotis, Konstantopoulos, Kostas, Vassilakopoulos, Theodoros P.

Get full text

A case report of Hodgkin lymphoma in a patient treated with ustekinumab for psoriasis by Charakopoulos, Emmanouil, Spyrou, Ioannis, Viniou, Nora-Athina, Giannakopoulou, Nefeli, Hatzidavid, Sevastianos, Diamantopoulos, Panagiotis Theodorou

“…Ustekinumab is a biological agent that inhibits interleukin 12 and 23 and has been approved for the treatment of moderate and severe plaque psoriasis. There…”
Get full text

An unusual case report of unilateral parotid gland sarcoidosis with spontaneous remission by Diamantopoulos, Panagiotis T, Charakopoulos, Emmanouil, Viniou, Nora-Athina, Diamantopoulou, Lydia, Gaggadi, Maria

“…Parotid gland sarcoidosis is a well-recognized, but uncommon disease entity. Parotidectomy is most commonly performed to establish the diagnosis and most…”
Get full text

High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents by Terpos, Evangelos, Katodritou, Eirini, Roussou, Maria, Pouli, Anastasia, Michalis, Eurydiki, Delimpasi, Sosana, Parcharidou, Agapi, Kartasis, Zafiris, Zomas, Athanasios, Symeonidis, Argiris, Viniou, Nora-Athina, Anagnostopoulos, Nikolaos, Economopoulos, Theofanis, Zervas, Konstantinos, Dimopoulos, Meletios A.

“…Objectives:  High serum lactate dehydrogenase (LDH) is associated with features of advanced disease and inferior survival in multiple myeloma. It is however…”
Get full text

Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients by Katodritou, Eirini, Terpos, Evangelos, Symeonidis, Argiris S., Pouli, Anastasia, Kelaidi, Charikleia, Kyrtsonis, Marie‐Christine, Kotsopoulou, Maria, Delimpasi, Sosana, Christoforidou, Anna, Giannakoulas, Nikolaos, Viniou, Nora‐Athina, Stefanoudaki, Ekaterini, Hadjiaggelidou, Christina, Christoulas, Dimitrios, Verrou, Evgenia, Gastari, Vassiliki, Papadaki, Sofia, Polychronidou, Genovefa, Papadopoulou, Athina, Giannopoulou, Evlambia, Kastritis, Efstathios, Kouraklis, Alexandra, Konstantinidou, Pavlina, Anagnostopoulos, Achilles, Zervas, Konstantinos, Dimopoulos, Meletios A.

“…Solitary plasmacytoma (SP) is a rare plasma cell dyscrasia characterized by the presence of bone or extramedullary plasma cell tumors. The treatment of choice…”
Get full text

Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5‐azacytidine—data from the Hellenic myelodysplastic syndrome study group by Mpakou, Vassiliki, Spathis, Aris, Bouchla, Anthi, Tsakiraki, Zoi, Kontsioti, Frieda, Papageorgiou, Sotirios, Bazani, Efthymia, Gkontopoulos, Konstantinos, Thomopoulos, Thomas, Glezou, Irene, Galanopoulos, Athanasios, Symeonidis, Argiris, Diamantopoulos, Panagiotis T., Viniou, Nora‐Athina, Kontandreopoulou, Christina‐Nefeli, Zafeiropoulou, Kalliopi, Kotsianidis, Ioannis, Lamprianidou, Eleftheria, Foukas, Periklis, Mpamias, Aristoteles, Pappa, Vasiliki

“…5‐azacytidine (5‐AZA) is considered the standard of care for patients with high‐risk myelodysplastic syndromes (MDS) and patients with acute myeloid leukemia…”
Get full text

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML by Adès, Lionel, Girshova, Larisa, Doronin, Vadim A., Díez-Campelo, María, Valcárcel, David, Kambhampati, Suman, Viniou, Nora-Athina, Woszczyk, Dariusz, De Paz Arias, Raquel, Symeonidis, Argiris, Anagnostopoulos, Achilles, Munhoz, Eduardo Ciliao, Platzbecker, Uwe, Santini, Valeria, Fram, Robert J., Yuan, Ying, Friedlander, Sharon, Faller, Douglas V., Sekeres, Mikkael A.

“…PANTHER is a global, randomized phase 3 trial of pevonedistat+azacitidine (n = 227) vs azacitidine monotherapy (n = 227) in patients with newly diagnosed…”
Get full text

The prognostic value of monosomal karyotype (MK) in higher‐risk patients with myelodysplastic syndromes treated with 5‐Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group by Papageorgiou, Sotirios G., Vasilatou, Diamantina, Kontos, Christos K., Kotsianidis, Ioannis, Symeonidis, Argiris, Galanopoulos, Athanasios G., Hatzimichael, Eleftheria, Megalakaki, Aekaterini, Poulakidas, Elias, Diamantopoulos, Panagiotis, Vassilakopoulos, Theodoros P., Zikos, Panagiotis, Papadaki, Helen, Mparmparousi, Despoina, Bouronikou, Eleni, Panayiotidis, Panayiotis, Viniou, Nora‐Athina, Pappa, Vassiliki

“…In this study, we investigated the incidence and prognostic impact of monosomal karyotype (MK) in 405 higher‐risk Myelodysplastic Syndromes (MDS) patients…”
Get full text

Real world data on the prognostic significance of monocytopenia in myelodysplastic syndrome by Diamantopoulos, Panagiotis T., Charakopoulos, Emmanouil, Symeonidis, Argiris, Kotsianidis, Ioannis, Viniou, Nora-Athina, Pappa, Vassiliki, Pontikoglou, Charalampos, Tsokanas, Dimitrios, Drakos, Georgios, Kourakli, Alexandra, Solomou, Elena, Hatzimichael, Eleftheria, Pouli, Anastasia, Kotsopoulou, Maria, Asmanis, Evangelos, Dimou, Maria, Panayiotidis, Panayiotis, Papageorgiou, Sotirios, Vassilopoulos, Georgios, Anagnostopoulos, Achilles, Vassilakopoulos, Theodoros, Papadaki, Helen, Galanopoulos, Athanasios

“…Monocytopenia is a common finding in patients with myelodysplastic syndrome (MDS), but although monocytes may exhibit prognostic significance in MDS due to…”
Get full text

Diagnosis and treatment complications of primary cardiac lymphoma in an immunocompetent 28-year old man: a case report by Bonou, Maria, Kapelios, Chris J, Marinakos, Athanasios, Adamopoulos, Stamatis, Diamantopoulos, Panagiotis, Foukas, Periklis G, Kaklamanis, Loukas, Korkolopoulou, Penelope, Barbetseas, John, Viniou, Nora-Athina

“…Primary cardiac lymphomas (PCL) represent extremely rare cardiac tumors which are accompanied by poor prognosis, unless they are timely diagnosed and treated…”
Get full text

Recurrent ETNK1 mutations in atypical chronic myeloid leukemia by Gambacorti-Passerini, Carlo B., Donadoni, Carla, Parmiani, Andrea, Pirola, Alessandra, Redaelli, Sara, Signore, Giovanni, Piazza, Vincenzo, Malcovati, Luca, Fontana, Diletta, Spinelli, Roberta, Magistroni, Vera, Gaipa, Giuseppe, Peronaci, Marco, Morotti, Alessandro, Panuzzo, Cristina, Saglio, Giuseppe, Usala, Emilio, Kim, Dong-Wook, Rea, Delphine, Zervakis, Konstantinos, Viniou, Nora, Symeonidis, Argiris, Becker, Heiko, Boultwood, Jacqueline, Campiotti, Leonardo, Carrabba, Matteo, Elli, Elena, Bignell, Graham R., Papaemmanuil, Elli, Campbell, Peter J., Cazzola, Mario, Piazza, Rocco

“…Despite the recent identification of recurrent SETBP1 mutations in atypical chronic myeloid leukemia (aCML), a complete description of the somatic lesions…”
Get full text

The outcome of patients with high‐risk MDS achieving stable disease after treatment with 5‐azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group by Papageorgiou, Sotirios G., Kontos, Christos K., Kotsianidis, Ioannis, Vasilatou, Diamantina, Symeonidis, Argyris, Galanopoulos, Athanasios, Bouchla, Anthi, Hatzimichael, Eleftheria, Repousis, Panagiotis, Zikos, Panagiotis, Viniou, Nora‐Athina, Poulakidas, Elias, Vassilakopoulos, Theodoros P., Diamantopoulos, Panagiotis, Diamantopoulos, Marios A., Mparmparousi, Despoina, Bouronikou, Eleni, Papadaki, Helen, Panayiotidis, Panayiotis, Pappa, Vasiliki

“…The demethylating factor 5‐azacytidine (5‐AZA) improves survival in intermediate‐2 and high‐risk myelodysplastic syndrome (MDS) patients [according to the…”
Get full text

Deregulation of Autophagy and Apoptosis in Patients with Myelodysplastic Syndromes: Implications for Disease Development and Progression by Tsekoura, Georgia, Agathangelidis, Andreas, Kontandreopoulou, Christina-Nefeli, Taliouraki, Angeliki, Mporonikola, Georgia, Stavropoulou, Maria, Diamantopoulos, Panagiotis T, Viniou, Nora-Athina, Aleporou, Vassiliki, Papassideri, Issidora, Kollia, Panagoula

“…(1) Background: Myelodysplastic neoplasms (MDSs) consist of a group of blood malignancies with a complex biological background. In this context, we…”
Get full text